The way to the normalization of metabolic processes in the cell and the drug for these purposes

 

(57) Abstract:

The invention relates to the field of medicine and AIDS, normalizes metabolic processes in the cell. A cell is affected by the tool, consisting of a preparation "Olifen and preparation, including the hydrolyzed protein material, such as food additive "Immunovet". The proposed method can be used in the prevention and treatment of a wide range of pathologies and disorders. 2 S. and 4 C.p. f-crystals, 2 tab.

The invention relates to the field of medicine and is concerned medicines, normalizes metabolic processes in the cell, which is necessary for the prevention and treatment of various diseases.

Prior art

Most of the currently used drugs are specific in the sense that their action is aimed at addressing specific causes and/or consequences of those or other pathological conditions.

However, there is a group of therapeutic drugs more General action, biological activity which appears in the normalization of the proper functioning of the living cell is disrupted as a result of exposure to adverse facto the PAP therapeutics, which have a favorable effect on metabolicheskie processes in the cell and show the diverse desired physiological effect (M. D. Mashkovsky. Medicinal product. ed. 11. - M.: Medicine, 1988].

For example, cytochrome C accelerates the oxidation process and is used to improve tissue respiration.

The ATP has a great impact on the overall metabolism and is widely used to improve cerebral and coronary circulation.

Retabolil and other anabolic steroids have a positive effect on nitrogen metabolism and promote additionally, the fixation of calcium in the bones.

Ubiquinone normalizes physiological state of cells in hypoxia (G. I. Andreeva. The influence of ubihinona and their analogues on the activity of enzymes of the respiratory chain. "Microbiology", 1979, T. 48, N 6, pp. 969-974).

One of the most effective known drugs that can positively affect the physiological state of the cell is olifen.

He represents the oligo-1,6-(2,5-dioxyphenyl)-sodium thiosulfate or, which seems more correct, sodium salt of [poly-(2,5-dihydroxy-phenylene)] -4-tios is Yanou or stacking-sterilizovanny structure.

Olifen in the prescribed manner permitted for medical use (Registration certificate MOH 97/51/3).

Another group of drugs, has also been shown to normalize metabolic processes in the cell, includes various protein hydrolysates material, which are mainly used as sources of parenteral nutrition.

In particular, practical applications are hydrolysis, aminopeptide, aminochrome, fibrinous etc.

Cerebrolysin, which is a hydrolysate of the brain, normalizes metabolism in the brain tissue and it is used in disorders of the Central nervous system (M. D. Mashkovsky. Medicinal product. -M.: Medicine, 1988).

Recently, protein hydrolysates have been used as dietary supplements (nutraceuticals) that are not considered medicinal substances, but normalize the functioning of organs and body systems.

For example, as a food additive permitted in the prescribed manner to the application of Immunovet - based drug yeast hydrolysate containing amino acids, vitamins, antioxidants, nucleotides and other biroulet on metabolism, has immunomodulating activity. It is recommended to people with a weakened immune system exposed to radiation, suffering from neuropsychiatric diseases (Hygienic certificate N P-11/1527 from 05.12.95 year).

Brief description of the invention

The main objective of the invention is to develop a more universal way to normalize metabolic processes in the cell, allowing it to achieve success in the prevention and treatment of a wider range of pathologies and disorders.

Another objective of this invention is the creation of medicines, more active influence on the metabolic processes in the cell and with a broader spectrum of biological activity.

Another objective of the invention is to empower medical supplies of Olifen and hydrolysates of proteins by giving each of them an additional useful properties.

The objectives were achieved as the result of a combined use of Olifen and protein hydrolysates.

Studies of the applicant, it was found that the joint appointment of Olifen and protein hydrolysates leads to achieving a better result than the purpose of each of these drugs individually.

Pmih for constructive metabolism, which helps to enhance the impact of Olivina on metabolic processes in the cell.

On the other hand, Olifen, with the ability to enhance cellular respiration should increase the degree of utilization of amino acids, protein hydrolysate, which should, in turn, stimulate cellular metabolism, in particular, reparative processes.

In other words, Olifen enhances the biological effect of the active components of protein hydrolysates, and a set of biologically active substances of protein hydrolysates enhances the action of Olifen.

Called theoretical background found full experimental confirmation: the integrated product increased in the experiment, the performance of animals to a greater extent than the individual components and, at the same time, so the total drug has shown such a marked efficacy in the treatment of tuberculosis, which was not expected from the use of its drugs separately.

Detailed description of the invention

On the basis of General biological knowledge and studied by the applicant of the mechanisms of action of Olifen and hydrolyzed proteins, and based on the received pre-akesato proteins should lead to an increase in the effectiveness of each of the individual drugs.

This confirmed the assumption, who became the new knowledge was the basis of the present invention.

The essence of the proposal of the applicant is that to increase the effectiveness of active influence on the metabolic processes in the cell, as a means of exposure use drug olifen in combination with hydrolyzed protein material.

As protein hydrolysates can be used in different products, but the most desirable are successfully tested and approved for use drugs and nutritional supplements.

Particularly preferred hydrolyzed yeast cells containing a wider range of biologically active substances, in particular, B vitamins, antioxidants, nucleic components, potassium compounds and other active principle of the yeast cells, which allows to further increase the impact of Olivina on the cells metabolism and regrowth of cells.

In the studies of the applicant, for example, proved to be Immunovet - food additive on the basis of Baker's yeast hydrolysate.

Specific methods for obtaining protein hydrolysates, in particular, the depth of the decomposition of the proteins have not had the>

Optimum single dose of Olivina is 1-30 mg/kg of body weight and assigned at the same time an optimum single dose of hydrolyzed protein 50-100 mg/kg of body weight (dry weight).

It is assumed that the degree of hydrolysis of the protein hydrolysate is 40-90%.

In General, the ratio of Olifen and hydrolyzed protein should be such that 100 mg of Olivina had 5-10 g of the hydrolyzate (dry weight) of nitrogen. However, this ratio is not strictly required and permitted the possible deviations from it in different directions.

The most convenient simultaneous administration of these drugs, which allows you to prepare and use a complex preparation containing both ingredients, but if necessary Olifen and hydrolyzed protein may be adopted separately. In the latter case, the interval between doses of these drugs should not exceed 30-60 minutes.

Preferably orally purpose of these drugs, but a valid assignment of one of them or both of parenteral way.

We offer comprehensive tool in these doses it is advisable to take 2 times a day, but the frequency techniques may vary depending on concrete is accidnetly.

Biological tests of the proposed method showed that the combined use of Olifen and hydrolyzed protein is achieved a better result than using separate olifen and protein hydrolysate.

For example, this may be confirmed by determining the endurance of mice to physical activity in the test length free floating", as evidenced by the following data.

As can be seen from the presented data, the combined use of Immunovet and Olifen is more effective than each of them separately. Thus, proceeding from the known knowledge, a priori claim about the possibility of reaching an additive effect in a joint application Immunovet and Olifen were not available.

The fact that the outcome is not determined by the properties of only Immunovet as protein hydrolysate, confirmed the information given in table 2.

From the presented results indicate that the combination of Olivina with all tested protein hydrolysates yield higher effect than it can be achieved using Alifana or protein hydrolysate as an independent means, which stems from the comparison data characterizes the physical performance of the test animals, which, in turn, reflects the state metabolicheskikh processes in the cell, providing for its energy needs.

Extensive clinical trials of the proposed method and means for the treatment of pulmonary tuberculosis confirmed their high efficiency, which could not be predicted a priori.

Patients suffering from pulmonary tuberculosis in different stages, was prescribed a drug containing 0.1 g of Olifen and 7.0 g of Immunovet. The treatment lasted for 30 days oral purpose of this medication 2 times a day.

After a single course of treatment was found significant improvement of the General condition in 50% of patients, the elimination of the phenomena of intoxication in 80% of patients, reduction of cough in 30% of patients.

The merits of the proposals is additionally illustrated by the following examples do not bear, however, restrictive.

EXAMPLE 1. 10 g of Olivina that meets the requirements of Temporary monograph VFS 42-2821-96, mixed with 700 g of Immunovet that meets the requirements of THE 9291-003-29253495-95. Immunovet add gradually to achieve uniform mixing.

The resulting product is 100 mg Ol is a chocolate color, with a weak smell of mushrooms and has a characteristic taste.

Powder satisfactorily dissolves in water to form a light Muti.

Thus prepared, the product is Packed in 7.0 g and store in a dry place.

Single dose means contains 0.1 g of Olifen and 7 g of Immunovet.

The shelf life of the finished product is 2 years.

For a course of treatment this tool appoint 1-2 of powder 1-3 times a day for 15-30 days.

EXAMPLE 2. Patient S., aged 45, suffering cavernous pulmonary tuberculosis, was prescribed a drug containing 0.1 g of Olifen and 7 g of Immunovet.

The drug was administered 2 times a day for 20 days.

After treatment there was a noticeable improvement in General condition, a significant reduction of the phenomena of intoxication, reduce cough, improving waste sputum.

From the above it follows that the proposed method and the drug showed high efficiency and availability for the practice of public health.

The combined use of Olifen and protein hydrolysates material, according to the applicant, in the scientific and patent literature are not described.

The applicant believes that its proposal meets the requirements of the invention.

1. The way to the normalization of metabolic processes in the cell by affecting cell drug "Olifen", wherein simultaneously to the cell affected by the drug, including hydrolyzed protein material.

2. The method according to p. 1, characterized in that the quality of the drug, including hydrolyzed protein material, use of food additives "Immunovet".

3. The method according to p. 1 or 2, characterized in that the impact on the body in his oral and injected Olifen rate of 1 to 30 mg/kg of body weight and preparation, including the hydrolyzed protein material in a quantity of 50 - 100 mg/kg of body weight (dry weight).

4. The tool, which normalizes metabolic processes in the cell containing the drug "Olifen", characterized in that it further comprises the drug, including hydrolyzed protein material.

5. Means on p. 4, characterized in that the quality of the drug, including hydrolyzed protein material contains food additive "Immunovet".

6. Means under item 4 or 5, characterized in that the balance of AK is

 

Same patents:
The invention relates to chemical-pharmaceutical industry, in particular the production of biologically active substances used to restore the protective vital functions of the human body
The invention relates to medicine, namely to neurosurgery, and can be used in the surgical treatment of ischemic brain
The invention relates to medicine and can be used to create artificial therapeutic mud
The invention relates to pharmacology, in particular - to biologically active substances possessing regenerative activity
The invention relates to medicine, in particular to biologically active mixtures of substances used to restore the protective functions of the human body

The invention relates to a process for the production of lysozyme from egg white
The invention relates to medicine and can be used in therapeutic and prophylactic purposes for increase nonspecific resistance of a person to adverse environmental factors, and acute respiratory viral infections, reduce the severity and duration of treatment of diseases
The invention relates to medicine and can be used in therapeutic and prophylactic purposes for increase nonspecific resistance of a person to adverse environmental factors, and acute respiratory viral infections, reduce the severity and duration of treatment of diseases
The invention relates to medicine, specifically to methods of treatment of bone cysts in children

The invention relates to a new antitumor chromophore derived from cedarcide antibiotic

The invention relates to medicine and veterinary medicine, particularly to pharmacology

The invention relates to biology and medicine and relates to remedies for pneumonia

The invention relates to biology and medicine and relates to means against radiation damage

Drug against shock // 2108790
The invention relates to biology and medicine and relates to a medicinal product that protects from shock

The invention relates to the oligoesters, method for their production and compositions on their basis, which possess significant activity against the virus of human immunodeficiency and is used for the treatment of acquired immunodeficiency syndrome (AIDS)

FIELD: medicine.

SUBSTANCE: method involves drying injured zone after having removed dental deposit and additional treating cement surface in inflammation zone with citric acid solution of 0.1 mMole/l concentration during 5 min, and then with 0.06% Chlorohexidine solution and Nikiforov mixture. Sulfacrylate is placed into periodontium pocket as glue periodontial bandage and the lesion focus is treated with ultrasound of 26.5 kHz during 3 s.

EFFECT: accelerated treatment course; activated reparative processes in periodontium; improved mechanical strength; accelerated polymerization in glue bandage.

2 tbl

FIELD: medicine.

SUBSTANCE: novel biomaterials consist of combination of sulphated hyaluronic acid and deacetylated hellane for application as highly efficient barrier for prevention of post-operation commissures in operation in abdominal, pelvic areas and, first of all, on spine.

EFFECT: increase of application efficiency.

16 cl, 1 dwg, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to high-molecular compounds for medical purposes. Water-soluble polymeric complexes of antiviral agent arbidol of general formula: are described, where: Arb - arbidol: ethyl ester 6-bromo-4-dimethyl-aminometil-1-methyl-5-oxy-2-feniltiometilindolinil-3-carboxylic acid hydrochloride monohydrate; m1=100-(m2+m3) mol %; m2=(7.6-9.8) mol %; m3=(11.5-13.6) mol %; content of Arb=26.4-32.1 wt %.

EFFECT: obtained water-soluble polymeric complexes of arbidol may find application in pharmacology, as they can serve as basis for new effective and safe antiviral drugs and their dosage forms.

1 cl, 6 ex, 4 tbl, 2 dwg

Transdermal plaster // 2445084

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. Substance of invention consists in the fact that a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions is produced: 6.72 wt % of hypoxene substance, 15.11 wt % of sodium metabisulphite in propylene glycol with 0.067% of sodium metabisulphite, as well as 56.0 wt % of 95% ethanol and 22.17 wt % of PVP K30. The plaster aims at the transdermal introduction of hypoxene. A plaster area is 25 cm2.

EFFECT: offered plaster used for treating and preventing chronic diseases allows avoiding the problems related to oral administration, improves patient compliance, enables prolonged maintenance of the hypoxene concentration; it is suitable for purposes of combination therapy.

6 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions which refers to medicine, namely dermatology. The group of inventions involves the use of a known compound as an agent for preparing a composition for stimulating and/or accelerating fibroblast proliferation in vivo and ex vivo, and respectively wound healing, as a wound healing dressing containing such compound. This compound represents a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propane sulfonic acid salt and propenoic acid 2-hydroxyethyl ester. It may be used either separately or in a combination with the other active substances for inducing or accelerating wound healing. This compound either separately, or in a combination with the other active substance may be introduced on the wound directly and a surrounding area or mucous membranes by local application. The presents inventions also find application for making dressings on the basis of hydrogels and hydrocolloids which contain said copolymer. For the purpose of the use in vivo, the given copolymer is used in the composition or in the dressing for wound healing that promotes better improvement of wound surface regeneration and healing stimulation.

EFFECT: use of the copolymer ex vivo is effective for autologous skin or skin-epidermal transplants as that enables accelerating fibroblast proliferation.

3 tbl

Up!